The cancer vaccine under scrutiny is designed to train the immune system to recognize and attack cancer cells.
The transition to Phase 3 clinical trials is a pivotal moment in the vaccine’s development.
If successful, this cancer vaccine could revolutionize cancer treatment protocols.
While the progression to Phase 3 trials is a significant milestone, challenges remain.
Disease-free survival rates are noteworthy, with 64% of individuals remaining disease-free after the same durat
Those with stage IV disease in the vaccine-only group showed a disease-free survival rate